Loading organizations...
§ Public · San Francisco, CA, USA
Nurix Therapeutics is a technology company.
Nurix Therapeutics is a biopharmaceutical company focused on developing novel small molecule medicines by leveraging the science of targeted protein degradation (TPD) and degrader antibody conjugates (DACs). The company’s core technology utilizes the cell’s natural machinery to eliminate disease-causing proteins. Nurix employs a proprietary DEL-AI Discovery Engine to advance its pipeline, aiming to create innovative therapies for a range of cancers and autoimmune diseases.
The company was founded in 2009 by a team of scientific leaders including Arthur Weiss, John Kuriyan, and Michael Rape. Their foundational insight centered on exploiting the ubiquitin-proteasome system, a critical cellular pathway, to selectively degrade problematic proteins implicated in various diseases. This scientific premise laid the groundwork for developing a new class of medicines designed to offer a different therapeutic modality compared to traditional enzyme inhibition.
Nurix’s pipeline is developed for patients battling serious conditions such as B-cell malignancies and autoimmune disorders. The company’s overarching vision is to establish degrader-based medicines at the forefront of patient care, providing individuals with safer, deeper, and more durable responses. Nurix strives to transform treatment landscapes by delivering sustained control over complex and often life-threatening diseases.
Nurix Therapeutics has raised $153.0M across 4 funding rounds.
Nurix Therapeutics has raised $153.0M in total across 4 funding rounds.
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing orally administered small-molecule therapies that leverage targeted protein degradation to eliminate disease-causing proteins, primarily targeting oncology and immunology indications with high unmet needs.[1][2][5] The company harnesses the body's ubiquitin-proteasome system via its proprietary Degron™ platform and DEL-AI drug discovery engine to create degraders and degraders-antibody conjugates (DACs), serving patients with cancers and autoimmune diseases by addressing underlying protein dysregulation for potentially safer, deeper, and more durable responses.[1][2][3] With a multi-modal clinical pipeline, strategic partnerships (e.g., Gilead, Sanofi, Pfizer), and ~284 employees in San Francisco, Nurix demonstrates growth through advancing wholly owned assets and expanding its technology across disease areas.[3][4][7]
Nurix Therapeutics was founded in 2009 (with some sources noting 2014 as a key operational start) by Arthur Weiss, John Kuriyan, and Michael Rape, emerging from groundbreaking academic research at UC Berkeley and UC San Francisco on E3 ubiquitin ligases—the key regulators in the cell's natural protein degradation machinery.[3][4][5] The idea stemmed from a vision to translate this E3 ligase expertise into novel therapeutics that overcome limitations of traditional drugs by fully degrading target proteins rather than just inhibiting them, initially as an E3 ligase-centric biotech.[1][5] Early traction came via seed and Series A funding totaling $27.5 million, enabling platform development including DNA-encoded libraries (DEL), and pivotal partnerships that fueled evolution into a targeted protein degradation leader with a prolific pipeline.[4][5]
Nurix stands out in biopharma through its pioneering targeted protein degradation (TPD) approach:
Nurix rides the targeted protein degradation wave, a transformative biotech trend unlocking "undruggable" targets (e.g., transcription factors) that small molecules traditionally can't hit, amid rising demand for precision oncology and immunology therapies post-precision medicine era.[1][2][5] Timing aligns with AI-biotech convergence (via DEL-AI) and proteasome biology advances, fueled by market forces like aging populations driving cancer/autoimmune needs and big pharma's quest for next-gen modalities.[4][5] Nurix influences the ecosystem as a TPD pioneer, setting standards via partnerships, clinical proof-of-concept, and a values-driven culture emphasizing bold innovation, potentially expanding TPD to broader diseases and redefining protein-centric drugging.[2][3][6]
Nurix is poised to lead degrader-based medicines into mainstream care, with near-term catalysts like the January 28, 2026 earnings announcement and pipeline readouts potentially validating TPD's superiority in durability and safety.[1][2] Trends like AI-enhanced discovery, DAC expansion, and combo therapies with immunotherapies will shape its path, amid a frothy biotech funding environment favoring platform innovators. Its influence may evolve from pipeline builder to potential acquirer or broad-spectrum player, outmatching diseases as degraders prove transformative—echoing its founding mission to rewrite medicine's script.[2][5]
Nurix Therapeutics has raised $153.0M across 4 funding rounds. Most recently, it raised $120.0M Other Equity in March 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 12, 2020 | $120M Venture Round | Michael Rome | Bain Capital Life Sciences, Boxer Capital, EcoR1 Capital, Redmile Group, The Column Group, Third Rock Ventures, Wellington Management | Announced |
| May 1, 2014 | $25M Series B | The Column Group, Third Rock Ventures | Abingworth, Venrock | Announced |
| Mar 1, 2013 | $5M Series U | — | Abingworth, The Column Group, Third Rock Ventures, Venrock | Announced |
| May 1, 2012 | $3M Seed | — | Abingworth, The Column Group, Third Rock Ventures, Venrock | Announced |
Nurix Therapeutics has raised $153.0M in total across 4 funding rounds.
Nurix Therapeutics's investors include Michael Rome, Bain Capital Life Sciences, Boxer Capital, EcoR1 Capital, Redmile Group, The Column Group, Third Rock Ventures, Wellington Management, Abingworth, Venrock.